How much revenue does AstraZeneca (AZN) generate?

AstraZeneca (AZN) generated $60.44B in total revenue in TTM through Q1 2026, with a net profit margin of 17.2%, equivalent to roughly $10.39B in net income — what remains after every operating cost, interest payment, and income tax has been paid.

What is the gross profit margin of AstraZeneca (AZN)?

AstraZeneca (AZN) reported a gross profit margin of 81.7% in TTM through Q1 2026, equivalent to $49.37B in gross profit on $60.44B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of AstraZeneca (AZN)?

AstraZeneca (AZN) reported an operating profit margin of 23.7% in TTM through Q1 2026, equivalent to $14.31B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of AstraZeneca (AZN)?

AstraZeneca (AZN) reported a net profit margin of 17.2% in TTM through Q1 2026, equivalent to $10.39B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is AstraZeneca (AZN) profitable?

Yes. AstraZeneca (AZN) reported $10.39B in net income for TTM through Q1 2026, with a net profit margin of 17.2%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does AstraZeneca (AZN) invest in research and development?

AstraZeneca (AZN) invested $14.56B in research and development during TTM through Q1 2026, roughly 24.1% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does AstraZeneca (AZN) spend on capital expenditures?

AstraZeneca (AZN) spent $5.20B on capital expenditures (CapEx) during TTM through Q1 2026, roughly 8.6% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does AstraZeneca (AZN) generate?

AstraZeneca (AZN) generated $9.11B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 15.1%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of AstraZeneca (AZN)?

AstraZeneca (AZN) had an effective tax rate of 19.5% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

How AstraZeneca Makes Money: 2026 Visual Revenue Map

AstraZeneca (AZN) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported April 29, 2026).

AstraZeneca discloses geographic revenue only in annual filings. to view the full breakdown.

Frequently asked questions

Data & methodology

AstraZeneca (AZN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation